Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
C105 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| C105 | DRUG | - |
Inclusion Criteria: * Males/females at least 18 years old and \< 65 years old, capable of understanding and complying with the protocol, including speaking and writing fluent English and having at least a 9th grade education * Clinically definite diagnosis per McDonald criteria of Multiple Sclerosi...
C105 is an investigational small molecule being studied for cognition disorders, including cognitive dysfunction in people with multiple sclerosis. It was evaluated in a Phase 2 trial in adults with MS-related cognitive impairment. C105 is not approved for any indication and remains in clinical development.
C105 is being developed by Cognition Therapeutics, Inc., which trades on the Nasdaq under the ticker CGTX. The company is the sponsor of the clinical program evaluating C105 in cognition disorders within the neurology therapeutic area.
C105 is in Phase 2 development. Its single registered trial, NCT00529581, was a Phase 2 study of C105 on cognitive dysfunction in persons with multiple sclerosis. That trial is now completed, and C105 is an investigational agent that has not been approved by the FDA.
C105 has been studied in one clinical trial, NCT00529581, titled A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis. The Phase 2 trial enrolled 150 participants in the United States, included adults 18 years and older of all sexes, and is completed.
The Phase 2 trial NCT00529581 evaluated C105 in 150 adults with cognition disorders and multiple sclerosis. It was a randomized, double-blind study conducted in the United States. Participants were 18 years or older, all sexes were eligible, and healthy volunteers were not enrolled.